Tumor Necrosis Factor Inhibitors
Comprehensive Dermatologic Drug Therapy, Page: 287-301.e7
2021
- 2Citations
- 286Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Antitumor necrosis factor (anti-TNF) alpha agents have become critical in the treatment of multiple dermatologic diseases. Initially, and still primarily, used for the treatment of psoriasis, multiple other conditions, including psoriatic arthritis and hidradenitis suppurativa have anti-TNF therapy, as a central therapeutic option. This chapter will review the potential benefits, as well as adverse effects of anti-TNF therapy, as well as cover the expanding targets for these treatments.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780323612111000267; http://dx.doi.org/10.1016/b978-0-323-61211-1.00026-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85143694702&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780323612111000267; https://dx.doi.org/10.1016/b978-0-323-61211-1.00026-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know